Selskabets formål er at drive handel, industri og finansiering samt anden dermed beslægtet virksomhed, herunder at drive virksomhed gennem datterselskaber
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 937.9 mio. | 13.2 mio. | 442.2 mio. | 254.1 mio. | 128 | |
CVR: 20575786
Secondary names: CIBA-GEIGY A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
The financial health of Novartis Healthcare A/S shows signs of instability, with a notable decline in profitability from 2023 to 2024, where profit dropped from 251 million DKK to 13 million DKK despite a slight revenue increase from 914 million DKK to 938 million DKK. The company's equity has also decreased significantly from 540 million DKK in 2023 to 254 million DKK in 2024, raising concerns about its financial stability and ability to sustain operations. Revenue trends indicate fluctuations, with a peak in 2020 at over 1 billion DKK, followed by a general decline in subsequent years. As a player in the pharmaceutical wholesale industry, the company may face challenges in maintaining its market position unless it addresses these financial concerns effectively.
AI-generated summary
companydata.dk